[Form 4] Travere Therapeutics, Inc. Insider Trading Activity
Travere Therapeutics director Suzanne Louise Bruhn received new equity awards, including 4,000 shares of common stock and options for 12,000 shares, as part of the company's non-employee director compensation program. These automatic grants, vesting over one year, increased her direct holdings to 32,750 shares of common stock. The filing details two transactions, categorizing the impact and sentiment as neutral.
[Form 4] Travere Therapeutics, Inc. Insider Trading Activity
Sandra Poole, a director at Travere Therapeutics, Inc. (TVTX), received equity compensation on May 19, 2026. This included 4,000 shares of common stock at no cost and a stock option for 12,000 shares with an exercise price of $42.26, set to expire in 2036. These grants were part of the company's non-employee director compensation program, with the stock option vesting over one year.
[Form 4] Travere Therapeutics, Inc. Insider Trading Activity
Travere Therapeutics director Gary A. Lyons received new equity awards as part of his board compensation, including 4,000 shares of common stock and options for 12,000 shares. These grants are part of the company’s 2018 Equity Incentive Plan for non-employee directors and vest over one year. This transaction is categorized as routine compensation rather than an open-market purchase, increasing Lyons' direct holdings to 61,500 common shares and 12,000 stock options.
Travere Therapeutics (TVTX) director sells 3,250 shares in Rule 10b5-1 trade
Travere Therapeutics director Timothy Coughlin sold 3,250 shares of common stock at $43.49 per share on May 15, 2026, under a pre-arranged Rule 10b5-1 trading plan. After this transaction, Coughlin directly holds 52,250 shares of TVTX. This sale was disclosed in a Form 4 SEC filing, indicating a moderate negative impact sentiment.
A Look At Travere Therapeutics (TVTX) Valuation After New US$525m Convertible Notes Refinancing
Travere Therapeutics recently refinanced with a US$525 million convertible senior notes offering, leading to questions about its current valuation after significant stock performance. While a common analyst narrative suggests the company is 20.5% undervalued based on the potential of drug FILSPARI for rare kidney disease, a look at its P/S ratio (7.4x) compared to peers (5.7x) indicates a more cautious outlook. Investors are advised to consider both bullish and cautious perspectives before making a decision.
Stephens Investment Management Group LLC Acquires 121,955 Shares of Travere Therapeutics, Inc. $TVTX
Stephens Investment Management Group LLC increased its stake in Travere Therapeutics (NASDAQ:TVTX) by 7.6% during the fourth quarter, purchasing an additional 121,955 shares. The institutional investor now owns 1,721,623 shares valued at approximately $65.8 million. The company recently reported strong quarterly earnings, surpassing analyst estimates with EPS of $0.05 and a 55.6% year-over-year revenue increase to $127.2 million.
(TVTX) Movement Within Algorithmic Entry Frameworks
This article analyzes Travere Therapeutics Inc. (NASDAQ: TVTX) through algorithmic entry frameworks, highlighting strong sentiment across all horizons and an exceptional 72.2:1 risk-reward setup. It outlines various institutional trading strategies, including a position trading strategy, momentum breakout strategy, and risk hedging strategy, supported by multi-timeframe signal analysis for near-term, mid-term, and long-term horizons.
[144] Travere Therapeutics, Inc. SEC Filing
Travere Therapeutics, Inc. (TVTX) has filed a Form 144 with the SEC, indicating a proposed sale of 3,250 shares of common stock with an aggregate market value of $141,182.59 by Wells Fargo Clearing Services. The shares were acquired on May 15, 2026, as restricted stock awards from the issuer. This filing provides details on the nature of the acquisition and confirms no other securities were sold by the person in the past three months.
Armistice Capital/Steven Boyd discloses 4,897,417 TVTX shares (5.27%)
Armistice Capital and Steven Boyd have disclosed a beneficial ownership of 4,897,417 shares, representing 5.27% of Travere Therapeutics (TVTX) common stock, through a joint Schedule 13G filing. The shares are directly held by Armistice Capital Master Fund Ltd., with Armistice Capital managing the voting and investment power. Steven Boyd, as the managing member of Armistice Capital, is deemed to beneficially own these shares, although the Master Fund disclaims direct beneficial ownership due to the investment management agreement.
Travere, Ligand Pharma announce FDA label expansion for Filspari
Travere Therapeutics and Ligand Pharmaceuticals have announced that the FDA has granted a label expansion for their drug Filspari. This expansion allows Filspari to be used in a broader patient population for certain kidney diseases. The article would detail the specifics of this label expansion and its implications for patients and the companies.
Travere’s US$525 Million Convertible Refi Might Change The Case For Investing In Travere Therapeutics (TVTX)
Travere Therapeutics recently completed a US$525 million offering of convertible senior notes to refinance existing debt and support commercialization and R&D. This move extends debt maturities at a lower interest rate, offering Travere greater financial flexibility for its FILSPARI drug and pipeline development. While the refinancing improves the balance sheet, the investment narrative still heavily relies on FILSPARI's uptake and regulatory success.
UBS Group AG Has $16.15 Million Position in Travere Therapeutics, Inc. $TVTX
UBS Group AG reduced its stake in Travere Therapeutics (NASDAQ:TVTX) by 29.1% in the fourth quarter, selling 173,554 shares and now holding 422,619 shares valued at $16.15 million. Company insiders, including the director and CEO, also sold shares totaling $15.9 million over the past three months. Despite insider selling, Travere Therapeutics reported strong earnings, beating estimates with $0.05 EPS and a 55.6% year-over-year revenue increase, leading analysts to rate it a "Moderate Buy" with a $47.83 consensus price target.
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 12, 2026
Travere Therapeutics announced that its Compensation Committee granted inducement equity awards to four new employees on May 10, 2026. These grants, totaling 48,800 shares of common stock, consist of stock options and restricted stock units (RSUs) and were made in accordance with Nasdaq Listing Rule 5635(c)(4). The grants are designed to induce the new employees to join the company, with vesting schedules tied to continued employment.
Travere Therapeutics launches first FDA-approved therapy for rare kidney disease FSGS.
Travere Therapeutics has received FDA approval for its first therapy targeting FSGS, a rare and severe kidney condition. This approval signifies a major advancement for patients with FSGS and underscores Travere's dedication to developing innovative treatments for rare diseases. The company is also currently conducting a Phase III trial for a treatment for classical homocystinuria.
State of New Jersey Common Pension Fund D Takes Position in Travere Therapeutics, Inc. $TVTX
The State of New Jersey Common Pension Fund D has acquired a new position in Travere Therapeutics (NASDAQ:TVTX), purchasing 28,904 shares valued at approximately $1.1 million in the fourth quarter. Analysts maintain a "Moderate Buy" consensus rating for TVTX with a target price of $47.83, following several price target upgrades. Despite strong Q1 earnings that surpassed estimates, some insiders have recently sold shares.
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Travere Therapeutics announced inducement grants in accordance with Nasdaq Listing Rule 5635(C)(4). This brief report, sourced from Refinitiv and Thomson Reuters, indicates a standard compliance or employee incentive related filing by the company.
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Travere Therapeutics, Inc. announced inducement equity grants to four new employees, totaling 48,800 shares of common stock. These grants, comprising stock options and restricted stock units (RSUs), were made on May 10, 2026, under Nasdaq Listing Rule 5635(c)(4). The grants are designed to incentivize new employees, with specific vesting schedules for both the stock options and RSUs.
Travere Therapeutics Issues New Convertible Notes to Refinance Debt
Travere Therapeutics successfully completed a public offering of $525 million in 0.50% Convertible Senior Notes due 2032, generating approximately $508.5 million in net proceeds. The company plans to use a significant portion ($350.9 million) to repurchase its 2029 notes, thereby extending its debt maturity profile. This move aims to reshape Travere's debt with a low coupon and equity-linked capital, though it might lead to future shareholder dilution.
Travere Therapeutics Completes $525 Million 0.50% Convertible Notes Offering Led by JPMorgan, Jefferies, Leerink
Travere Therapeutics successfully completed a $525 million registered offering of 0.50% Convertible Senior Notes due 2032, with J.P. Morgan Securities, Jefferies, and Leerink Partners leading the deal. The company plans to use the net proceeds, estimated at $508.5 million, to repurchase a portion of its 2.25% convertible notes due 2029 and for general corporate purposes. Additionally, Travere Therapeutics executed an indenture with U.S. Bank Trust Company to govern the terms of these new 2032 notes.
[8-K] Travere Therapeutics, Inc. Reports Material Event
Travere Therapeutics, Inc. has completed a registered underwritten public offering of $525.0 million aggregate principal amount of 0.50% Convertible Senior Notes due 2032. The company estimates net proceeds of $508.5 million, with $350.9 million allocated to repurchase existing 2.25% senior convertible notes due 2029. The remaining proceeds will be used for general corporate purposes, including commercialization and R&D.
Travere prices upsized $475.0 million convertible senior notes offering to refinance 2029 convertible notes
Travere Therapeutics has priced an upsized offering of $475.0 million in convertible senior notes maturing in 2029. The primary purpose of this offering is to refinance its existing callable 2.25% convertible senior notes that are due in 2028. This strategic move aims to manage the company's debt profile and extend maturity dates.
Travere Therapeutics Insider Sold Shares Worth $1,092,657, According to a Recent SEC Filing
Travere Therapeutics (TVTX) insider Noah Rosenberg recently sold 100,000 shares of the company's common stock for a total value of $1,092,657. This transaction, occurring on May 6, 2026, was disclosed in a Form 4 filing with the SEC. Following the sale, Rosenberg still directly owns 75,000 shares of Travere Therapeutics.
Travere Therapeutics (TVTX) Heads Into Q1 2026 With Sharply Narrowed Trailing Losses Testing Bull Case
Travere Therapeutics (TVTX) is approaching its Q1 2026 earnings report after significantly narrowing its trailing 12-month losses from US$4.06 per share in Q4 2024 to US$0.56 in Q4 2025, despite swinging back to a quarterly loss in Q4 2025. The company's revenue has increased significantly, primarily driven by new rare kidney disease products, which has led to a potential valuation gap compared to analyst targets and its discounted cash flow fair value. Investors are closely watching how Q1 2026 margins and loss levels will evolve to validate the bullish case for future profitability and growth.
Travere Therapeutics to Participate at Upcoming Investor Conferences - May 7, 2026
Travere Therapeutics, Inc. announced its participation in three upcoming investor conferences in May and June 2026: the BofA Securities 2026 Health Care Conference, the 2026 Jefferies Global Healthcare Conference, and the Goldman Sachs 47th Annual Global Healthcare Conference. The company will provide live webcasts of its presentations on its investor website, with replays available for 30 days following each event. Travere Therapeutics focuses on developing and delivering life-changing therapies for rare diseases.
Travere Therapeutics Inc SEC Filings
This page provides a comprehensive resource for Travere Therapeutics (TVTX) SEC filings, including annual reports, quarterly earnings, material events, and insider trading forms. It highlights recent Form 8-K filings detailing financial results and regulatory developments, such as FDA communications regarding FILSPARI. Additionally, the page offers AI-powered summaries of these documents to help investors quickly grasp key information.
Travere Therapeutics Prices Upsized $475 Million Debt Offering
Travere Therapeutics has priced an upsized debt offering of $475 million. The article mentions this in conjunction with Unity Software's Q4 earnings, which showed a 35% year-over-year revenue increase to $609 million, although the company reported a quarterly loss of 66 cents per share.
Travere Therapeutics Insider Sold Shares Worth $988,875, According to a Recent SEC Filing
Travere Therapeutics' President and CEO, Eric D. Satzman, recently sold 80,000 shares of the company's stock for a total value of $988,875 at an average price of $12.36 per share. This transaction was disclosed in a Form 4 filing with the SEC. Following this sale, Satzman still directly owns 347,716 shares of Travere Therapeutics.
Travere Therapeutics to Participate at Upcoming Investor Conferences
Travere Therapeutics, Inc. (Nasdaq: TVTX) announced its participation in three upcoming investor conferences: the BofA Securities 2026 Health Care Conference on May 13, 2026; the 2026 Jefferies Global Healthcare Conference on June 3, 2026; and the Goldman Sachs 47th Annual Global Healthcare Conference 2026 on June 8, 2026. Live webcasts of these presentations will be available on the investor page of Travere’s website, with replays accessible for 30 days. The company's mission is to develop and deliver life-changing therapies for rare diseases.
[424B5] Travere Therapeutics, Inc. Prospectus Supplement (Debt Securities)
Travere Therapeutics, Inc. is offering $475 million in 0.50% convertible senior notes due 2032, with an option for an additional $50 million for underwriters. The notes are convertible into cash, shares, or a combination, based on specific conditions and an initial conversion price of approximately $64.90 per share. Proceeds will be used to repurchase a portion of its outstanding 2.25% convertible senior notes due 2029 and for general corporate purposes.
Travere Therapeutics to Participate at Upcoming Investor Conferences
Travere Therapeutics, Inc. announced its participation in several upcoming investor conferences in May and June 2026. Management will be presenting at the BofA Securities 2026 Healthcare Conference, the 2026 Jefferies Global Healthcare Conference, and the Goldman Sachs 47th Annual Global Healthcare Conference. Live webcasts of these presentations will be available on the company's website.
Travere Therapeutics Insider Sold Shares Worth $360,000, According to a Recent SEC Filing
An insider at Travere Therapeutics recently sold 30,000 shares of company stock for a total value of $360,000. This information was disclosed in a recent SEC filing. The sale took place at an average price of $12.00 per share.
Travere Therapeutics prices $475 million convertible notes
Travere Therapeutics has priced an underwritten offering of $475 million in convertible senior notes due 2032, an increase from the initial $400 million, with an option for underwriters to purchase an additional $50 million. The company expects net proceeds of approximately $460 million, which will be used to repurchase outstanding 2029 notes and for general corporate purposes. This move follows mixed financial results in Q1 2026 but positions Travere for expected profitability in 2026, according to analyst forecasts.
Travere Therapeutics (TVTX) CMO exercises options and sells 22,485 shares
Travere Therapeutics Chief Medical Officer Jula Inrig exercised 20,000 employee stock options and converted 4,250 performance-based restricted stock units (PSUs), subsequently selling a total of 22,485 shares between May 4-6, 2026. Many of these transactions were conducted under a pre-arranged Rule 10b5-1 trading plan and included "sell to cover" sales for tax withholding. Following these activities, Inrig retains significant holdings, including 113,238 common shares, 34,500 stock options, and 8,500 PSUs.
Tax-driven share sale follows PSU vesting at Travere (TVTX)
Travere Therapeutics' Chief Commercial Officer, Peter Heerma, sold 2,174 shares of TVTX stock at $46.65 per share to cover tax obligations following the vesting of 4,250 performance-based restricted stock units (PSUs). The sale was a mandatory "sell to cover" transaction, not a discretionary one, and occurred after the company met a FILSPARI cumulative net revenue milestone. Heerma now directly holds 140,684 shares, with further PSU vesting contingent on continued service and additional performance milestones.
Travere Therapeutics Inc SEC Filings
This page provides a comprehensive overview of Travere Therapeutics Inc.'s (TVTX) SEC filings, including 10-K, 10-Q, 8-K, and Form 4 documents. It details how Stock Titan enhances these filings with AI-powered summaries and real-time updates to help investors monitor the company's financial reporting, regulatory developments, and insider transactions in the rare disease sector. The most recent filing was an 8-K on August 6, 2025.
Travere therapeutics director Roy Baynes sells $209,925 stock
Roy D. Baynes, a director at Travere Therapeutics, recently sold 4,500 shares of common stock for $209,925 after exercising options. The transaction was part of a pre-arranged trading plan, and despite the sale, Baynes still holds 37,500 shares. The company's stock has seen a significant 121% gain over the past year, though it recently missed Q1 2026 earnings and revenue expectations.
Travere Therapeutics CFO Cline sells $115,368 in company stock
Travere Therapeutics CFO, Christopher R. Cline, recently sold company shares totaling $115,368 across two transactions to cover tax withholding obligations associated with vested restricted stock units. These sales were mandated by the company's equity incentive plans. The company's stock has seen a significant 121% return over the past year, and analysts predict profitability for the current fiscal year.
Travere therapeutics CMO Inrig sells $1.02 million in stock
Jula Inrig, Chief Medical Officer at Travere Therapeutics, Inc., sold over $1 million worth of company stock through various transactions, including planned sales and "sell to cover" for tax obligations. These sales followed an acquisition of shares through employee stock options and vested performance-based restricted stock units. The company's stock has surged, with analysis suggesting it is undervalued despite trading near its 52-week high, and analysts predict profitability for 2026, even after recent mixed Q1 2026 financial results.
Travere Therapeutics (NASDAQ: TVTX) CRO sells shares after PSU vesting event
Travere Therapeutics' Chief Research Officer, William E. Rote, sold 2,763 shares of common stock at $43.95 per share under a pre-arranged Rule 10b5-1 trading plan. This sale followed the vesting of 4,250 performance-based restricted stock units due to meeting a cumulative FILSPARI net revenue target, and he also received a new grant of 8,500 performance-based units. After these transactions, Rote directly holds 115,474 common shares.
Director at Travere (NASDAQ: TVTX) sells 4,500 pre-planned shares
Travere Therapeutics director Roy D. Baynes exercised stock options for 4,500 shares at $18.27 each and simultaneously sold them for $46.65 per share in a pre-planned transaction on May 5, 2026. This sale was conducted under a Rule 10b5-1(c) trading plan adopted on November 17, 2025. After these transactions, Baynes directly owns 37,500 shares of Travere Therapeutics common stock.
Travere therapeutics director sells $360,000 in shares
Jeffrey A. Meckler, a director at Travere Therapeutics, sold 8,000 shares of the company's common stock for $360,000 on May 4, 2026. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan. The company recently reported mixed Q1 2026 financial results and plans to offer $400 million in convertible senior notes.
Travere Therapeutics CFO Cline sells $115,368 in company stock
Travere Therapeutics CFO Christopher R. Cline sold shares totaling $115,368, primarily to cover tax obligations related to vested performance restricted stock units, not as discretionary trades. The sales occurred after Cline acquired 4,250 shares upon the vesting of performance-based restricted stock units tied to the company's FILSPARI revenue milestone, which saw a 96% growth. Despite recent mixed Q1 2026 financial results with an EPS and revenue miss, analysts predict profitability for the company this year, and Travere Therapeutics plans a $400 million convertible senior notes offering.
William Rote sells 9,100 TVTX shares; 2,763 restricted shares vest (TVTX)
William E. Rote, an insider at Travere Therapeutics, Inc. (TVTX), sold 9,100 shares on April 22, 2026, for a total of $355,719.00, according to a recent Form 144 filing. Additionally, the filing indicates that 2,763 restricted shares are scheduled to vest on May 4, 2026, as part of his compensation. This transaction was processed through Fidelity Brokerage Services LLC.
Analysts Offer Insights on Healthcare Companies: GeneDx Holdings (WGS), Pfizer (PFE) and Travere Therapeutics (TVTX)
Analysts from various firms have provided recent ratings and price targets for several healthcare companies. GeneDx Holdings (WGS) received a reiterated Buy rating from BTIG and an upgrade from TipRanks – Google, indicating a Strong Buy consensus. Pfizer (PFE) maintained a Hold rating from Erste Group and Bernstein, while Travere Therapeutics (TVTX) garnered a reiterated Buy rating from Guggenheim and Piper Sandler, signaling a Strong Buy consensus.
Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
Travere Therapeutics announced its intention to offer $400 million in convertible senior notes due 2032, with an option for underwriters to purchase an additional $60 million. A portion of the proceeds will be used to repurchase outstanding 2.25% senior convertible notes due 2029, with the remainder allocated for general corporate purposes. J.P. Morgan, Jefferies, and Leerink Partners are acting as joint book-running managers.
8,000 Travere (TVTX) shares sold as director exercises options
Travere Therapeutics director Jeffrey A. Meckler exercised stock options for 8,000 shares at $16.33 per share and subsequently sold all 8,000 shares at $45.00 per share in an open-market transaction. This sale, conducted under a pre-arranged Rule 10b5-1(c) trading plan, leaves Meckler with 87,500 shares of Travere common stock. The transactions highlight a planned insider sale following the exercise of fully vested options.
Jula Inrig sells 20,000 shares (NASDAQ: TVTX) — Form 144 filing
Jula Inrig, a reporting person for Travere Therapeutics (NASDAQ: TVTX), filed a Form 144 detailing several stock dispositions. The filing reports a sale of 20,000 shares on May 4, 2026, for $900,000, along with prior sales in April 2026 totaling 8,233 shares. It also indicates 2,174 shares tied to Performance Restricted Stock Unit vesting on May 4, 2026.
Insider sale filing — TVTX (NASDAQ: TVTX) Peter Heerma sold 7,215 shares
Peter Heerma, an insider at Travere Therapeutics, Inc. (TVTX), recently filed a Form 144 indicating an intended sale of 2,174 shares related to Performance Restricted Stock Unit Vesting on May 4, 2026. The filing also disclosed a previous sale by Heerma of 7,215 shares on April 14, 2026, for $302,515.98. This insider activity is described as neutral, routine, and typical for compensation vesting followed by shareholder selling.
Travere therapeutics director Roy Baynes sells $431,145 in stock.
Roy D. Baynes, a director at Travere Therapeutics, Inc. (NASDAQ:TVTX), sold 9,750 shares of common stock for $431,145 on May 1, 2026, pursuant to a pre-arranged trading plan. On the same day, he acquired 9,750 shares by exercising stock options at $6.82 per share. Following these transactions, Baynes directly holds 37,500 shares and 9,750 derivative shares.
Travere Therapeutics Analysts Increase Their Forecasts Following Q1 Earnings
Travere Therapeutics reported a profitable first quarter with earnings beating analyst estimates, despite sales falling short. Following the earnings announcement, several analysts from HC Wainwright & Co., Wedbush, Citigroup, and TD Cowen increased their price targets for Travere Therapeutics (TVTX) shares, maintaining Buy or Outperform ratings. The company's CEO highlighted the landmark approval of FILSPARI and its foundational role in IgAN and FSGS as key drivers for substantial future growth.
